Skip to main content
< Back to news
Barbara Krebs-Pohl, new Chair of the Board of Directors of OneChain Immunotherapeutics
 03.06.2025

OneChain Immunotherapeutics Announces the Appointment of Barbara Krebs-Pohl as New Chair of the Board of Directors

OneChain Immunotherapeutics (OCI), a clinical-stage biotechnology company focused on the development of CAR T therapies for the treatment of oncological diseases, based at the Barcelona Science Park, has announced the appointment of Barbara Krebs-Pohl as the new Chair of the Board of Directors. Her appointment strengthens OneChain’s vision to continue advancing its pipeline and achieving new milestones in the development of cell therapies.

Barbara Krebs-Pohl is a highly respected leader in the biotechnology sector with over 27 years of experience, particularly in business strategy and alliance development. She has held key positions at renowned companies, including MorphoSys, where she served as Chief Business Officer, leading strategies that generated $2.9 billion in revenue. Her expertise in strategic partnerships and acquisition integration, notably with Constellation Pharmaceuticals Inc., played a pivotal role in strengthening MorphoSys’s oncology leadership, contributing to its recent acquisition by Novartis.

Krebs-Pohl has also served on the board of HI-Bio, which was acquired by Biogen in 2024, and is currently the Managing Director of the Foundation for Stem Cell Research and Regenerative Medicine. Additionally, she is a Partner and Managing Director at Viopas Venture Consulting, where she advises emerging biotechnology companies on growth and strategic partnerships.

Barbara’s appointment comes at a pivotal moment for OneChain, as the company enters its next phase of expansion. “I am thrilled to be joining OneChain at such an important stage, with first clinical signals from their frontrunner program in a phase 1 trial,” Barbara Krebs-Pohl said. “The team’s deep expertise in applied science, coupled with a strong commitment to addressing urgent medical needs, makes this an exciting opportunity. I look forward to contributing to the company’s next steps in corporate development and helping to further advance their CAR T therapies and allogeneic platform.”

Laura Rodríguez, Board Member and Principal at Invivo Capital and Pablo Menéndez, co-founder and CSO of OCI, also expressed their enthusiasm about the appointment, highlighting the significance of this new phase for the company: “We are delighted to welcome Barbara as Chair of the Board of Directors of OneChain. Her experience in strategic leadership and business development will be key to guiding its continued success.”

Stefanos Theoharis, CEO of OCI, also shared his excitement about Barbara’s new role, emphasizing the importance of her leadership in steering the company towards its future goals. “As our pipeline continues to evolve and deliver positive data and patient benefits, Barbara’s experience and proven track record in company growth, business development and strategic decision-making will be invaluable. I am very pleased to welcome Barbara as the new Chair of the BOD and to work closely with her for the continued success of our company”, he added.

» Link to the news: OneChain Immunotherapeutics website [+]